Transcode Therapeutics Inc (RNAZ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -34,661 | -16,755 | -18,546 | -17,565 | -6,843 |
| Depreciation Amortization | 114 | 535 | 517 | 99 | 43 |
| Income taxes - deferred | 226 | N/A | N/A | N/A | N/A |
| Other Working Capital | -211 | -352 | -1,082 | 1,309 | 432 |
| Other Operating Activity | 15,015 | 3,236 | 1,037 | 395 | 1,102 |
| Operating Cash Flow | $-19,516 | $-13,336 | $-18,075 | $-15,763 | $-5,267 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -7 | -22 | -36 | -101 | -252 |
| Net Acquisitions | 2 | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $-4 | $-22 | $-36 | $-101 | $-252 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 8,855 | 16,401 | 15,909 | 6 | 26,335 |
| Other Financing Activity | 22,668 | 0 | 0 | 0 | -819 |
| Financing Cash Flow | $31,523 | $16,401 | $15,909 | $6 | $25,517 |
| Beginning Cash Position | 5,811 | 2,768 | 4,968 | 20,826 | 828 |
| End Cash Position | 17,814 | 5,811 | 2,768 | 4,968 | 20,826 |
| Net Cash Flow | $12,003 | $3,044 | $-2,201 | $-15,857 | $19,998 |
| Free Cash Flow | |||||
| Operating Cash Flow | -19,516 | -13,336 | -18,075 | -15,763 | -5,267 |
| Capital Expenditure | -7 | -22 | -36 | -101 | -255 |
| Free Cash Flow | -19,523 | -13,358 | -18,110 | -15,863 | -5,522 |